These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20624867)

  • 1. Policy alternatives for treatments for rare diseases.
    Panju AH; Bell CM
    CMAJ; 2010 Nov; 182(17):E787-92. PubMed ID: 20624867
    [No Abstract]   [Full Text] [Related]  

  • 2. Policymaking for Orphan Drugs and Its Challenges.
    Rhee TG
    AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.
    Clarke JT
    CMAJ; 2006 Jan; 174(2):189-90. PubMed ID: 16415465
    [No Abstract]   [Full Text] [Related]  

  • 4. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 6. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 7. Adopting an orphan.
    Rinaldi A
    EMBO Rep; 2005 Jun; 6(6):507-10. PubMed ID: 15940282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHS defends expanded 340B drug discounts.
    Lee J
    Mod Healthc; 2014 Jun; 44(24):9. PubMed ID: 25137989
    [No Abstract]   [Full Text] [Related]  

  • 10. Confusion over Article 8.
    Tambuyzer E
    EMBO Rep; 2005 Aug; 6(8):690. PubMed ID: 16065056
    [No Abstract]   [Full Text] [Related]  

  • 11. Why we should care about ultra-rare disease.
    Harari S
    Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoption agents.
    Wapner J
    Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
    [No Abstract]   [Full Text] [Related]  

  • 14. Open letter to prime minister David Cameron and health secretary Andrew Lansley.
    Nicholl DJ; Hilton-Jones D; Palace J; Richmond S; Finlayson S; Winer J; Weir A; Maddison P; Fletcher N; Sussman J; Silver N; Nixon J; Kullmann D; Embleton N; Beeson D; Farrugia ME; Hill M; McDermott C; Llewelyn G; Leonard J; Morris M
    BMJ; 2010 Nov; 341():c6466. PubMed ID: 21081599
    [No Abstract]   [Full Text] [Related]  

  • 15. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 16. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

  • 17. Reforming the Orphan Drug Act for the 21st Century.
    Sarpatwari A; Kesselheim AS
    N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
    [No Abstract]   [Full Text] [Related]  

  • 18. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
    Roberts EA; Herder M; Hollis A
    CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
    [No Abstract]   [Full Text] [Related]  

  • 19. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
    Brabers AE; Moors EH; van Weely S; de Vrueh RL
    Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.